Zenas BioPharma (ZBIO) Balance Sheet

As of Dec 31, 2025 (end of fiscal 2025), Zenas BioPharma reported total assets of $383.64M and total liabilities of $141.50M. Shareholders' equity was $242.14M, down 22.5% from $312.46M a year earlier. Total debt stood at $79.96M against $343.19M in cash and short-term investments, a net cash position of $263.23M. That puts debt-to-equity at 0.33, compared with 0.00 a year earlier.

Zenas BioPharma Balance Sheet Analysis

Values in billions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Balance sheet showing assets, liabilities, and shareholders' equity for Zenas BioPharma, Inc. (ZBIO) - Annual data in billions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022
Current Assets
Cash and Cash Equivalents	0.11	0.32	0.06	0.07
Short-Term Investments	0.23	0.03	0.00	0.00
Cash & Short-Term Investments	0.34	0.35	0.06	0.07
Accounts Receivable	0.00	0.00	0.00	0.00
Inventory	0.00	0.00	0.00	0.00
Other Current Assets	0.01	0.01	0.00	0.00
Total Current Assets	0.35	0.36	0.06	0.07
Non-Current Assets
Property, Plant & Equipment (Net)	0.00	0.00	0.00	0.00
Long-Term Investments	0.02	0.00	0.00	0.00
Other Non-Current Assets	0.01	0.01	0.01	0.00
Total Non-Current Assets	0.03	0.01	0.01	0.01
Total Assets	0.38	0.37	0.07	0.07
Current Liabilities
Accounts Payable	0.01	0.02	0.01	0.01
Short-Term Debt	0.00	0.00	0.00	0.00
Accrued Liabilities	0.04	0.04	0.01	0.02
Other Current Liabilities	0.05	0.04	0.02	0.02
Total Current Liabilities	0.06	0.06	0.02	0.03
Non-Current Liabilities
Long-Term Debt	0.08	0.00	0.02	0.00
Other Non-Current Liabilities	0.00	0.00	0.25	0.24
Total Non-Current Liabilities	0.08	0.00	0.27	0.24
Total Liabilities	0.14	0.06	0.29	0.27
Stockholders' Equity
Common Stock	0.00	0.00	0.00	0.00
Retained Earnings	-0.77	-0.39	-0.23	-0.19
Accumulated Other Comprehensive Income	0.00	0.00	0.00	0.00
Additional Paid-in Capital	1.01	0.70	0.00	0.00
Shares Outstanding	0.05	0.04	0.04	0.04
Total Stockholders' Equity	0.24	0.31	-0.23	-0.19
Total Liabilities & Equity	0.38	0.37	0.07	0.07

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Zenas BioPharma Balance Sheet

How much debt does Zenas BioPharma have?

Zenas BioPharma had total debt of $79.96M as of Dec 31, 2025, against $343.19M in cash and short-term investments. Its debt-to-equity ratio was 0.33. Total debt was $1.00M a year earlier.

What are Zenas BioPharma's total assets?

Zenas BioPharma reported total assets of $383.64M as of Dec 31, 2025, up 3.7% from $369.97M a year earlier. Total liabilities were $141.50M.

What is Zenas BioPharma's shareholders' equity?

Zenas BioPharma's shareholders' equity was $242.14M as of Dec 31, 2025, or about $4.44 of book value per share.

What is the debt-to-equity ratio?

The debt-to-equity ratio divides a company's total debt by its shareholders' equity. It shows how much of the business is financed with borrowed money; normal levels vary widely by industry. Full definition